HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human albumin solution for resuscitation and volume expansion in critically ill patients.

AbstractBACKGROUND:
Human albumin solutions are used in a range of medical and surgical problems. Licensed indications are the emergency treatment of shock and other conditions where restoration of blood volume is urgent, burns, and hypoproteinaemia. Human albumin solutions are more expensive than other colloids and crystalloids.
OBJECTIVES:
To quantify the effect on mortality of human albumin and plasma protein fraction (PPF) administration in the management of critically ill patients.
SEARCH STRATEGY:
We searched the Cochrane Injuries Group trials register, Cochrane Central Register of Controlled Trials, Medline, Embase and BIDS Index to Scientific and Technical
PROCEEDINGS:
Reference lists of trials and review articles were checked, and authors of identified trials were contacted. The search was last updated in August 2004.
SELECTION CRITERIA:
Randomised controlled trials comparing albumin/PPF with no albumin/PPF, or with a crystalloid solution, in critically ill patients with hypovolaemia, burns or hypoalbuminaemia.
DATA COLLECTION AND ANALYSIS:
We collected data on the participants, albumin solution used, mortality at the end of follow up, and quality of allocation concealment. Analysis was stratified according to patient type.
MAIN RESULTS:
We found 32 trials meeting the inclusion criteria and reporting death as an outcome. There were 1632 deaths among 8452 trial participants. For hypovolaemia, the relative risk of death following albumin administration was 1.01 (95% confidence interval 0.92-1.10). This estimate was heavily influenced by the results of the SAFE trial, which contributed 91% of the information (based on the weights in the meta-analysis). For burns, the relative risk was 2.40 (1.11-5.19) and for hypoalbuminaemia the relative risk was 1.38 (0.94-2.03). There was no substantial heterogeneity between the trials in the various categories (chi2 = 21.86, df = 25, p = 0.64). The pooled relative risk of death with albumin administration was 1.04 (0.95-1.13).
CONCLUSIONS:
For patients with hypovolaemia there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trial.
PLAIN LANGUAGE SUMMARY:
There is no evidence that giving human albumin to replace lost blood in critically ill or injured people improves survival when compared to giving saline. Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein), is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood products or combinations can be used. The review of trials found no evidence that albumin reduces the risk of dying. Albumin is very expensive in which case it may be better to use cheaper alternatives such as saline for fluid resuscitation.
AuthorsAlessandro Liberati, Lorenzo Moja, Ivan Moschetti, Gian Franco Gensini, Roberto Gusinu
JournalInternal and emergency medicine (Intern Emerg Med) Vol. 1 Issue 3 Pg. 243-5 ( 2006) ISSN: 1828-0447 [Print] Italy
PMID17120476 (Publication Type: Journal Article, Review)
Chemical References
  • Albumins
  • Blood Proteins
  • Serum Albumin
  • Serum Globulins
  • Solutions
  • plasma protein fraction
  • Serum Albumin, Human
Topics
  • Albumins (therapeutic use)
  • Blood Proteins (therapeutic use)
  • Critical Illness (mortality, therapy)
  • Humans
  • Randomized Controlled Trials as Topic
  • Resuscitation (methods)
  • Serum Albumin
  • Serum Albumin, Human
  • Serum Globulins
  • Solutions

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: